March 1, 2021
Markets Insider
ORIG3N develops treatments for rare genetically inherited diseases with a focus on heart, liver and neurodegenerative indications. Read more
ORIG3N develops treatments for rare genetically inherited diseases with a focus on heart, liver and neurodegenerative indications. Read more
Co-Founder & CEO
Robin Y. Smith
Ultragenyx is seen as one of ORIG3N's top competitors. Ultragenyx's headquarters is in Novato, California, and was founded in 2010. Like ORIG3N, Ultragenyx also works within the Biotechnology industry. Ultragenyx generates 9,034% of ORIG3N's revenue.
March 1, 2021
Markets Insider
March 1, 2021
FinanzNachrichten
March 1, 2021
PharmaTimes
No recent acquisitions found related to ORIG3N
Since ORIG3N was founded in 2014, it has participated in 5 rounds of funding. In total ORIG3N has raised $36.0M. ORIG3N's last funding round was on Apr 2020 for a total of $350.0K
Since ORIG3N was founded in 2014, it has participated in 5 rounds of funding. In total ORIG3N has raised $36.0M. ORIG3N's last funding round was on Apr 2020 for a total of $350.0K
No recent investments found related to ORIG3N